<DOC>
	<DOC>NCT00379847</DOC>
	<brief_summary>This study will investigate the application of a vasopressin antagonist in the treatment of hyponatremia most likely caused by inappropriate AVP secretion. The population studied will include patients with euvolemic or hypervolemic hyponatremia.</brief_summary>
	<brief_title>An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia</brief_title>
	<detailed_description />
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Serum sodium levels less than or equal 130mEq/L Euvolemic or Hypervolemic hyponatremia Clinical evidence of volume depletion or dehydration Untreated severe hypothyroidism, hyperthyroidism, or adrenal insufficiency Uncontrolled bradyor tachyarrhythmias requiring pacemaker placement or treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>hyponatremia</keyword>
	<keyword>hypervolemic</keyword>
	<keyword>euvolemic</keyword>
	<keyword>treatment outcomes</keyword>
	<keyword>YM087</keyword>
</DOC>